Welcome to our dedicated page for Mannkind Corporation news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind Corporation stock.
MannKind Corporation (Nasdaq: MNKD) is a leading biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative inhaled therapeutic products for patients with serious unmet medical needs. The company focuses on treating diseases such as diabetes, pulmonary arterial hypertension, and nontuberculous mycobacterial (NTM) lung disease.
Their flagship product, Afrezza, is an ultra-rapid-acting inhaled insulin designed to improve glycemic control in adults with diabetes. This product features a dry powder formulation of human insulin delivered via a small, portable inhaler.
MannKind's latest advancements include the initiation of a Phase 3 trial for Clofazimine Inhalation Suspension aimed at treating refractory NTM lung disease. The trial, named ICoN-1, will evaluate the efficacy and safety of the drug when added to standard therapy. This initiative is a response to the increasing global prevalence of NTM lung infections, which pose significant health risks and complications for patients.
Additionally, MannKind is progressing with a Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases such as idiopathic pulmonary fibrosis (IPF). This study will assess the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers.
The company's technological prowess is underlined by its proprietary Technosphere® dry-powder technology, which facilitates rapid and effective delivery of medicines to the deep lung. This technology, combined with their inhalation devices, is used to develop new treatments that can either act locally in the lungs or enter the systemic circulation, depending on the medical need.
In a strategic partnership, MannKind has in-licensed Pulmatrix's iSPERSE™ technology to enhance their formulation capabilities. This collaboration also includes exchanging MannKind's Cricket® inhaler technology to aid in the development of inhaled treatments for migraine and other neurological diseases.
Financially, MannKind continues to invest in R&D to expand its product pipeline and enhance its technological platforms. The company’s partnerships, such as the recent agreement with Pulmatrix, are also set to strengthen MannKind's market position in the biopharmaceutical landscape.
With a dedicated team and a robust pipeline, MannKind Corporation remains at the forefront of developing effective inhaled therapies, striving to improve patient outcomes and quality of life.
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will participate in a virtual presentation at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 2:00 PM (ET). Interested parties can access the live webcast through the company's website, with a replay available for 14 days after the event.
MannKind focuses on developing inhaled therapeutic products for endocrine and orphan lung diseases, utilizing dry-powder formulations and inhalation devices for effective medicine delivery. The company is committed to addressing medical needs related to diabetes and pulmonary diseases.
MannKind Corporation (Nasdaq: MNKD) reported a total revenue of $100 million for 2022, reflecting a 32% increase from 2021. The fourth quarter revenues reached $36 million, a significant 188% rise year-over-year. Notable contributors include $12 million from Afrezza, with a gross margin of 92%, and $5 million from the newly acquired V-Go product. However, collaborations and services saw a 23% decline year-over-year, primarily due to the conclusion of a partnership with United Therapeutics. The company held $173 million in cash and equivalents at year-end, supporting ongoing R&D investments, including a Phase 3 trial for Afrezza in pediatrics.
MannKind Corporation (Nasdaq: MNKD) announced that its inhaled Technosphere Insulin (TI) demonstrated faster glucose control in a recent pilot study, lowering peak glucose levels 30 minutes faster than traditional rapid-acting insulin via an Automated Insulin Delivery (AID) system. The study involved 26 adults with type 1 diabetes, with TI achieving a lower post-prandial glucose from 45 to 120 minutes post-meal. MannKind plans a larger study to further explore TI's efficiency compared to traditional insulin methods, aiming to improve mealtime glucose control significantly.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., February 16, 2023 — MannKind Corporation (Nasdaq: MNKD) is set to release its 2022 fourth quarter and full year financial results on February 23, 2023, at 5:00 PM ET. The management will host a conference call to discuss these results and provide corporate updates. Presenters include CEO Michael Castagna and CFO Steven B. Binder. Interested parties can tune in via MannKind's website, with a replay available for 14 days. The company focuses on developing innovative therapeutic products for serious medical needs, particularly in endocrine and orphan lung diseases, utilizing dry-powder formulations and inhalation devices.
MannKind Corporation (Nasdaq: MNKD), focused on inhaled therapeutic products for endocrine and orphan lung diseases, announced that CEO Michael Castagna will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 1:40 pm (ET). Interested parties can access the live webcast through the Company’s website, with the replay available for 14 days post-event. MannKind aims to develop innovative therapies for conditions like diabetes and pulmonary arterial hypertension using advanced delivery systems.
MannKind Corporation (Nasdaq: MNKD) will present at the Lytham Partners Investor Select Conference on January 31, 2023, at 9:00 am ET. CEO Michael Castagna and CFO Steven B. Binder will participate in this virtual event, which aims to discuss the company’s innovations in inhaled therapeutic products for endocrine and orphan lung diseases. The presentation will be accessible on the company's website and archived for later viewing. Attendees can also engage in one-on-one meetings with management by contacting Lytham Partners.
MannKind focuses on meeting serious medical needs in diabetes and pulmonary diseases through advanced delivery systems.
MannKind Corporation (Nasdaq: MNKD) announced the advancement of clofazimine inhalation suspension (MNKD-101) to an adaptive Phase 2/3 study, paving the way for a potential treatment for nontuberculous mycobacterial (NTM) lung disease. Published findings highlight the product's tolerability and toxicokinetics, suggesting it could reduce systemic toxicity associated with oral treatments. An estimated 86,000-180,000 individuals in the U.S. suffer from NTM lung disease, which is on the rise. FDA has designated MNKD-101 as both an orphan lung and qualified infectious disease product (QIDP), indicating its potential significance in addressing this growing health concern.
MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, PharmD, will present at the 2023 Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 AM PST in San Francisco, California. Interested parties can listen to the webcast on the company's website, which will also be archived for replay. MannKind focuses on developing innovative therapeutic products for endocrine and orphan lung diseases, emphasizing rapid medicine delivery through their signature inhalation devices.
MannKind Corporation (Nasdaq: MNKD) announced promising results from the Afrezza with Basal Combination (ABC) Study, presented on November 10, 2022, at the Annual Diabetes Technology Meeting. Technosphere Insulin (TI) demonstrated a faster peak effect, occurring 30 minutes sooner, and significantly reduced postprandial glucose excursions at 60 minutes compared to subcutaneous insulins, with values of 57.9 mg/dL versus 101.4 mg/dL. No severe hypoglycemia was reported, highlighting TI's potential as a pump-sparing option for diabetes patients.
MannKind Corporation (MNKD) reported 3Q 2022 total revenues of $32.8 million, marking a 48% increase compared to 3Q 2021. Afrezza net revenue rose 11% to $10.8 million, with total revenues for the nine-month period reaching $63.7 million. The company experienced a 67% revenue growth in its Endocrine Business Unit, driven by Afrezza and V-Go demand. However, the net loss for 3Q 2022 was $14.4 million, reflecting increased SG&A and interest expenses. Gross profit for Afrezza improved to 81% margin compared to 61%
FAQ
What is the current stock price of Mannkind Corporation (MNKD)?
What is the market cap of Mannkind Corporation (MNKD)?
What is MannKind Corporation's primary focus?
What is Afrezza?
What recent advancements has MannKind made?
What is Technosphere<sup>®</sup> technology?
What is the significance of the iSPERSE<sup>™</sup> technology partnership?
What diseases does MannKind target with its products?
Where can I find more information about MannKind Corporation?
Is MNKD-101 approved for use?
What is the significance of the ICoN-1 trial?
How does MannKind's partnership with Pulmatrix benefit its R&D capabilities?
